Novartis meningitis vaccine used at 2nd US campus

(AP)—Swiss drug maker Novartis says a second U.S. university is using its new vaccine against meningitis B.

Novartis said Monday that the , Bexsero, is being used at the University of California Santa Barbara until March 7 to help protect 20,000 students and staff after an .

The vaccine shot for the B strain of the meningitis bacteria is approved for use in Europe, Australia and Canada, but not yet for general use in the United States.

But the U.S. Food and Drug Administration has now approved the use of Bexsero twice in response to outbreaks at U.S. college campuses. It is the first vaccine against the B strain of meningitis.

Princeton University says almost 5,300 people got the vaccine last year in an effort to halt an outbreak there.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Princeton vaccine reaches 90 percent of eligible

Dec 13, 2013

Princeton University officials say more than 90 percent of the eligible students and staff received a meningitis vaccine this week as part of the university's effort to halt an outbreak.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

Dec 22, 2014

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.